Professional Documents
Culture Documents
Liver Investigation: Testing Marker Utility in Steatohepatitis
Liver Investigation: Testing Marker Utility in Steatohepatitis
in Steatohepatitis
Fact Sheet
Project Information
Overall budget
€ 47 281 406,63
Start date End date
1 November 2017 31 October 2022 EU contribution
€ 15 797 881
Coordinated by
UNIVERSITY OF NEWCASTLE
UPON TYNE
United Kingdom
Objective
Strongly associated with the epidemics of obesity and type 2 diabetes that are
testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is
an increasingly common cause of advanced liver disease that is characterized by
substantial inter-patient variability in severity and rate of progression. It is currently
assessed by liver biopsy, an invasive, costly and risky procedure. The lack of
noninvasive biomarkers has hampered patient care and impeded drug development
by complicating conduct of clinical trials.The overarching aim of LITMUS is to
develop, robustly validate and advance towards regulatory qualification biomarkers
that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis
stage. This will be achieved through a goal-oriented, tri-partite collaboration
delivering a definitive and impartial evaluation platform for biomarkers, bringing
1 of 18
together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD
and the pharmaceutical industry)? (ii) Independent academics with expertise in the
evaluation of medical test/biomarker performance? and (iii) Biomarker researchers
and developers (academic or commercial).
LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon
foundations laid by the EU-funded FLIP/EPoS projects and long-established,
successful scientific collaborations amongst many of Europe’s leading clinical-
academic centres, LITMUS is at a unique advantage due to its existing large-scale
patient cohorts, bioresources and multi-omics datasets. Consortium members are
internationally recognised experts with substantial relevant expertise supporting the
program’s clear focus on biomarker identification, validation and accelerating
EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker
validity for NAFLD at scale and pace: supporting drug development and the targeting
of medical care and limited healthcare resources to those at greatest need.
Programme(s)
Topic(s)
H2020-JTI-IMI2-2016-09-two-stage
Funding Scheme
Coordinator
Participants (55)
2 of 18
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 1 180 910
EU contribution
€ 684 250
EU contribution
€ 260 500
EU contribution
€ 1 073 015
3 of 18
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF
CAMBRIDGE
United Kingdom
EU contribution
€ 598 005
OREBRO UNIVERSITY
Sweden
EU contribution
€ 312 500
EU contribution
€ 403 017,50
UNIVERSITAET BERN
Switzerland
EU contribution
€ 435 000
4 of 18
Website Contact the organisation
EU contribution
€ 1 818 750
PERSPECTUM LTD
United Kingdom
EU contribution
€ 250 000
EU contribution
€ 601 250
EU contribution
5 of 18
EU contribution
€ 1 427 093
EU contribution
€ 540 033,75
EU contribution
€ 365 160,75
UNIVERSITE D'ANGERS
France
EU contribution
€ 122 500
EU contribution
€ 167 100
LINKOPINGS UNIVERSITET
Sweden
EU contribution
€ 99 600
HELSINGIN YLIOPISTO
Finland
EU contribution
€ 202 500
EU contribution
€ 273 328,75
EU contribution
€ 118 350
EU contribution
€ 78 487,50
EU contribution
€ 80 722,50
EU contribution
€ 105 081,25
8 of 18
UNIVERSITA CATTOLICA DEL SACRO CUORE
Italy
EU contribution
€ 80 653,75
EU contribution
€ 406 206,25
UNIVERSITAETSKLINIKUM AACHEN
Germany
EU contribution
€ 248 076,25
EU contribution
€ 118 115
9 of 18
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 54 075
ANTAROS MEDICAL AB
Sweden
EU contribution
€ 231 275
EU contribution
€ 61 263,75
IXSCIENT LIMITED
United Kingdom
EU contribution
€ 344 375
10 of 18
Middlesex Secondary Education
Establishments)
EU contribution
€ 56 968,75
EU contribution
€ 61 680
GENFIT
France
EU contribution
€0
EU contribution
€0
11 of 18
Address Activity type
One, Glass Wharf Private for-profit entities
BS2 0ZX Bristol (excluding Higher or
Secondary Education
Establishments)
EU contribution
€1
EU contribution
€0
EU contribution
€0
12 of 18
Website Contact the organisation
PFIZER LIMITED
United Kingdom
EU contribution
€0
EU contribution
€0
SOMALOGIC INC
United States
EU contribution
€0
EU contribution
13 of 18
EU contribution
€0
EU contribution
€0
EU contribution
€0
NOVARTIS PHARMA AG
Switzerland
EU contribution
€0
EU contribution
€0
ASTRAZENECA AB
Sweden
EU contribution
€0
ECHOSENS
France
EU contribution
€0
RESOUNDANT, INC.
United States
15 of 18
United States
EU contribution
€0
EU contribution
€0
EU contribution
€0
ALLERGAN LIMITED
United Kingdom
EU contribution
€0
EU contribution
€0
EU contribution
€0
EU contribution
€0
17 of 18
Last update: 20 September 2021
Record number: 212225
Permalink: https://cordis.europa.eu/project/id/777377
18 of 18